JHVEPhoto ResMed ( NYSE: RMD ) shares fell Wednesday after Wolfe Research downgraded the MedTech, citing risks to the company’s CPAP (continuous positive airway pressure) device business from a potential label expansion for Eli Lilly’s ( NYSE: LLY ) GLP-1 agonist tirzepatide. Wolfe Analyst Mike Polark lowered.